WHO names SynAct Pharma oral resomelagon among six dengue candidates
WHO listed SynAct’s oral therapy resomelagon as one of six dengue drug candidates with supporting efficacy data for further clinical development, per a Lancet Microbe review. SynAct expects Phase 2 RESOVIR-2 results from Part 1 in 2026, pending regulatory feedback.
The World Health Organization listed SynAct Pharma’s oral therapy resomelagon as one of six dengue candidates with supporting efficacy data for further clinical development in a Lancet Microbe review. Ongoing Phase 2 RESOVIR-2 results from Part 1 are expected in 2026, pending regulatory feedback.